期刊文献+

上皮性卵巢癌组织趋化因子CXCL14与金属基质蛋白酶2表达相关性研究 被引量:1

The expression and clinical significance of the epithelial ovarian cancer tissue chemotactic factor CXCL14 and matrix metalloproteinase 2
原文传递
导出
摘要 目的观察上皮性卵巢癌组织趋化因子CXCL14与基质金属蛋白酶2 (MMP-2)表达。方法选取2015年5月至2017年12月,陕西省宁强县天津医院收治的上皮性卵巢癌患者78例,均手术留取其肿瘤组织(卵巢癌组),另外选取卵巢交界性肿瘤组织30例份(交界性肿瘤组),卵巢良性肿瘤组织20例份(良性肿瘤组),其中畸胎瘤7例,浆液性囊腺瘤5例,黏液性囊腺瘤4例,纤维瘤4例。采用免疫组化SP法检测三组CXCL14、MMP-2表达,分析卵巢癌CXCL14、MMP-2表达与患者临床病理参数的关系及CXCL14、MMP-2之间的关系。结果卵巢癌组CXCL14阳性表达率均低于交界性肿瘤组及良性肿瘤组,差异有统计学意义(χ~2=28.146、32.388,P<0.05),MMP-2阳性表达率均高于交界性肿瘤组及良性肿瘤组,差异有统计学意义(χ~2=5.524、9.568,P<0.05)。卵巢癌组织CXCL14表达与肿瘤TNM分期、淋巴结转移及腹水有关(χ~2=5.435、4.780、4.967,P<0.05),MMP-2表达与卵巢癌分化程度、TNM分期、淋巴结转移及腹水均有关(χ~2=8.969、22.772、19.855、18.332,P<0.05)。卵巢癌组织CXCL14、MMP-2表达呈负相关(r=-0.438,P<0.05)。结论卵巢癌组织趋化因子CXCL14低表达、MMP-2高表达,二者的表达变化参与卵巢癌的发生发展。 Objective To understand the expression and clinical significance of epithelial ovarian cancer tissue chemotactic factor CXCL14 and Matrix metalloproteinase 2. Methods Ovarian cancer tissues were collected from 78 patients with epithelial ovarian cancer(cancer group).Meanwhile,ovarian tissues from 30 cases with borderline ovarian tumors(borderline tumor group)and 20 cases with benign ovarian tumors(benign tumor group)were also collected.The expression levels of CXCL14 and MMP-2 in ovarian tissues were determined by the immunohistochemical SP method.The correlation between CXCL14 and MMP-2 and the clinical significance were analyzed and stated. Results The positive expression rate of CXCL14 in ovarian cancer group was significantly lower than the other two groups(χ^2=28.146,32.388,P〈0.05),while the positive expression rate of MMP-2 was significantly higher(χ^2=5.524,9.568,P〈0.05).The expression of CXCL14 in ovarian cancer was related to TNM stage,lymph node metastasis and ascites(χ^2=5.435,4.780,4.967,P〈0.05),while the expression of MMP-2 was related with tumor differentiation,TNM stage,lymph node metastasis and ascites(χ^2=8.969,22.772,19.855,18.332,P〈0.05).The expression of CXCL14 was negatively correlated with the expression of MMP-2 in ovarian cancer tissues(r=-0.438,P〈0.05). Conclusions The low expression of chemokine CXCL14 and high expression of MMP-2 in ovarian cancer tissues is closely related to the occurrence and development of ovarian cancer.
作者 赵艳芳 何訸 ZHAO Yan-fang;HE He(Department of Obstetrics and gynecology,Tianjin Hospital of Ningqiang,Ningqiang,Shaanxi 724400,China)
出处 《中国预防医学杂志》 CAS CSCD 2018年第10期757-760,共4页 Chinese Preventive Medicine
基金 四川省软科学研究计划项目(2017ZR0063)
关键词 卵巢癌 趋化因子CXCL14 基质金属蛋白酶2 Ovarian cancer Chemokine CXCL14 Matrix metalloproteinase 2
  • 相关文献

参考文献7

二级参考文献80

  • 1李敏,王文福,汪青.宫颈癌中MMP-2及TIMP-2的表达及其临床意义[J].解剖与临床,2004,9(4):241-243. 被引量:7
  • 2肖春花,冯玉梅,李晓青,郝希山.基质金属蛋白酶2 mRNA表达量与乳腺癌转移的关系及临床意义[J].中华外科杂志,2005,43(9):599-602. 被引量:4
  • 3Davidson B,Reich R,Berner A,et al.Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels[J].Eur J Cancer,2001,37:2040.
  • 4Manenti L,Paganoni P,Floriani I,et al.Expression levels of vascular endothelial growth factor,matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian rcinoma[J].Eur J Cancer,2003,39:1948.
  • 5Tae-Joong Kim MD,Seung Bae Rho PhD,Yoon-La Choi MD,et al.High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis[J].Human Pathology,2006,37:906.
  • 6D Belotti,P Paganoni,L Manenti A,et al.Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells:implications for ascites formation[J].Cancer Res,2003,63:5224.
  • 7M Rauvala,U Puistola T.Turpeenniemi-Hujanen,et al.Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor[J].Gynecologic Oncology,2005,99:656.
  • 8DA Fishman,Y Liu,SM Ellerbroek,et al.Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells[J].Cancer Res,2001,61:3194.
  • 9Lee JK,Hong YJ,Han CJ,et al.Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients:which is the optimal specimen[J].Int J Oncol,2000,17(2):149.
  • 10H Yabushita,M Shimazu,M Noguchi,et al.Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer[J].Oncol Rep,2003,10:89.

共引文献38

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部